In a prospective, noncomparative 4-week clinical study of 46 patients, 63% of patients had exuding leg ulcers for at least 6 months and and 20 of these patients had exuding leg ulcers for over 12 months:^{1, *}

• There was a significant reduction in mean wound area from 10.1cm² at baseline to 5.1cm² at four weeks (p<0.001) and ulcers healed in five subjects (11%)
• The surrounding skin improved or remained stable in all but one subject
• When compared with pre-study dressing, there was a significant reduction in reported ulcer pain for Versiva^® XC^TM dressing, both with the dressing in place (p<0.001) and on dressing removal (p<0.001)
• Final investigator ratings for 45 subjects, most were ‘excellent’ for ease of application (89%), ease of removal (96%), conformability (67%) and overall performance (58%)

This study was funded by ConvaTec Inc.

* in a protocol of care that included Versiva^® XC^TM dressing with compression and concomitant medications

In a prospective, noncomparative 4-week clinical study of 23 patients with an average pressure duration of one year:^{2 †}

• In 61% of subjects clinicians reported that the wound condition had either healed or improved
• More than 90% of responsive subjects rated Versiva^® XC^TM dressing as cushioning, soothing and comfortable
• 91% of clinicians rated Versiva^® XC^TM dressing as “excellent” or “good” for non traumatic dressing removal
• Skin condition either healed, improved or remained stable in 87% of subjects
• Clinicians rated protection of the surrounding skin as “good” or “excellent’’ in 79% of subjects at final evaluation
• Clinicians rated ease of application as “excellent” or “good” in 92% of cases and ease of removal as “excellent” or “good” in 96% ofcases at final evaluation

This study was funded by ConvaTec Inc.

† in a protocol of care that included Versiva^® XC^TM dressing, pressure reducing/relieving devices were mandatory